Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2025

Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from SPROUT randomised control trial

Br J Dermatol 2025;193:1120–1127 Doi: 10.1093/bjd/ljaf305

Zhang W,

Zhang Z,

Paller et al. evaluated the long-term efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis through the 52-week Phase III SPROUT trial. The study assessed whether clinical responses were sustained after the placebo-controlled period and whether outcomes differed between treatment sequences.

Keywords:

June 2025

Deucravacitinib in patients with plaque psoriasis who screened positive for psoriatic arthritis: improvements in joint pain and the impact of musculoskeletal symptoms

Dermatol Ther (Heidelb) 2025 DOI: 10.1007/s13555-025-01428-9

Varga S,

Choi JC,

Zhong Y,

Bili A,

Merola et al. undertook a post hoc analysis of prospective cohorts that compared the effects of deucravacitinib vs placebo and vs apremilast on joint pain, and the impact of musculoskeletal symptoms, at Weeks 16 and 24 in the pooled POETYK PSO-1 and PSO-2 populations who self-reported joint symptoms on the PASE questionnaire. Patients who screened positively for PsA reported greater improvements in joint pain and peripheral joint disease with deucravacitinib vs placebo at Week 16 and vs apremilast at Week 24. Findings from this pooled analysis suggest that deucravacitinib may be used to treat both dermatologic and joint symptoms effectively in patients with psoriasis and probable arthritis.